BioSpace News Archive

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the third quarter ended September 30, 2021, and provided recent business highlights.

Neurocrine Biosciences, Inc. announced that members of the management team will participate at the following investor conferences.

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021.

Avidity Biosciences, Inc. (Nasdaq: RNA), today reported financial results for the third quarter and nine months ended September 30, 2021 and highlighted recent corporate progress.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, is providing a company update and third quarter 2021 financial results.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the third quarter ended September 30, 2021.

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, reported financial results for the quarter ended September 30, 2021.

Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2021, which include:

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, announced that it has agreed to acquire Eton Bioscience, a privately held provider of synthetic biology products and services.